David A. Ehrmann to Hypoglycemic Agents
This is a "connection" page, showing publications David A. Ehrmann has written about Hypoglycemic Agents.
Connection Strength
1.505
-
Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. Diabetologia. 2017 09; 60(9):1656-1661.
Score: 0.494
-
The effect of an education programme (MEDIAS 2 BSC) of non-intensive insulin treatment regimens for people with Type 2 diabetes: a randomized, multi-centre trial. Diabet Med. 2017 08; 34(8):1084-1091.
Score: 0.121
-
Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Feb; 82(2):524-30.
Score: 0.119
-
Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. Diabetes. 2016 Feb; 65(2):520-6.
Score: 0.109
-
Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013 Dec; 98(12):4646-54.
Score: 0.095
-
Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2008 Apr; 4(4):215-22.
Score: 0.064
-
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005 Apr; 54(4):1150-6.
Score: 0.052
-
Polycystic ovary syndrome. N Engl J Med. 2005 Mar 24; 352(12):1223-36.
Score: 0.052
-
Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab. 2003 Nov; 88(11):5137-44.
Score: 0.048
-
Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril. 2003 Apr; 79(4):932-7.
Score: 0.046
-
Weight loss and ß-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial. Obesity (Silver Spring). 2022 08; 30(8):1579-1588.
Score: 0.044
-
Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2021 12; 44(12):2775-2782.
Score: 0.041
-
Withdrawal of medications leads to worsening of OGTT parameters in youth with impaired glucose tolerance or recently-diagnosed type 2 diabetes. Pediatr Diabetes. 2020 12; 21(8):1437-1446.
Score: 0.039
-
Association of Habitual Daily Physical Activity With Glucose Tolerance and ß-Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study. Diabetes Care. 2019 08; 42(8):1521-1529.
Score: 0.035
-
Insulin-lowering therapeutic modalities for polycystic ovary syndrome. Endocrinol Metab Clin North Am. 1999 Jun; 28(2):423-38, viii.
Score: 0.035
-
Attenuation of hyperinsulinemia in polycystic ovary syndrome: what are the options? J Endocrinol Invest. 1998 Oct; 21(9):632-5.
Score: 0.033
-
Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018 04 01; 103(4):1233-1257.
Score: 0.032
-
Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest. 1997 Aug 01; 100(3):530-7.
Score: 0.031
-
Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes. 2007 Apr; 56(4):1153-9.
Score: 0.015